Epirubicin
Salivary Gland Cancer
OncoC4, Inc.Phase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Salivary Gland Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide OncoC4, Inc. | Phase 2 | B |
Pembrolizumab OncoC4, Inc. | Phase 2 | B |
Casodex European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | B |
Zoladex National Cancer Center Hospital East | Phase 2 | B |
Inno-206 European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | B |
View all 17 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →